These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31615114)

  • 1. Metabolism, Transport and Drug-Drug Interactions of Silymarin.
    Xie Y; Zhang D; Zhang J; Yuan J
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31615114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2.
    Bi X; Yuan Z; Qu B; Zhou H; Liu Z; Xie Y
    Phytomedicine; 2019 Feb; 54():98-108. PubMed ID: 30668388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milk thistle in liver diseases: past, present, future.
    Abenavoli L; Capasso R; Milic N; Capasso F
    Phytother Res; 2010 Oct; 24(10):1423-32. PubMed ID: 20564545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).
    Miranda SR; Lee JK; Brouwer KL; Wen Z; Smith PC; Hawke RL
    Drug Metab Dispos; 2008 Nov; 36(11):2219-26. PubMed ID: 18687803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
    Albassam AA; Frye RF; Markowitz JS
    Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
    Kidd P; Head K
    Altern Med Rev; 2005 Sep; 10(3):193-203. PubMed ID: 16164374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.
    Lynch KD; Montonye ML; Tian DD; Arman T; Oyanna VO; Bechtold BJ; Graf TN; Oberlies NH; Paine MF; Clarke JD
    Phytother Res; 2021 Jun; 35(6):3286-3297. PubMed ID: 33587330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
    Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
    Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silybin and its congeners: from traditional medicine to molecular effects.
    Křen V; Valentová K
    Nat Prod Rep; 2022 Jun; 39(6):1264-1281. PubMed ID: 35510639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.
    Bijak M
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29125572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
    Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
    Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silybin and silymarin--new and emerging applications in medicine.
    Gazák R; Walterová D; Kren V
    Curr Med Chem; 2007; 14(3):315-38. PubMed ID: 17305535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review.
    Soleimani V; Delghandi PS; Moallem SA; Karimi G
    Phytother Res; 2019 Jun; 33(6):1627-1638. PubMed ID: 31069872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin.
    Tvrdý V; Pourová J; Jirkovský E; Křen V; Valentová K; Mladěnka P
    Med Res Rev; 2021 Jul; 41(4):2195-2246. PubMed ID: 33587317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silybin and silymarin--new effects and applications.
    Kren V; Walterová D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):29-41. PubMed ID: 16170386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
    Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Patrick KS; Markowitz JS
    Drug Metab Dispos; 2013 Sep; 41(9):1679-85. PubMed ID: 23835761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2.
    Xu P; Zhou H; Li YZ; Yuan ZW; Liu CX; Liu L; Xie Y
    Front Pharmacol; 2018; 9():1115. PubMed ID: 30416442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silymarin and Its Role in Chronic Diseases.
    Neha ; Jaggi AS; Singh N
    Adv Exp Med Biol; 2016; 929():25-44. PubMed ID: 27771919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies.
    Yuan ZW; Li YZ; Liu ZQ; Feng SL; Zhou H; Liu CX; Liu L; Xie Y
    Pharmacol Res; 2018 Feb; 128():153-166. PubMed ID: 28958806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.
    Federico A; Dallio M; Loguercio C
    Molecules; 2017 Jan; 22(2):. PubMed ID: 28125040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.